Enanta Pharmaceuticals Inc (ENTA) Share Price

I violated my own covenant by buying ENTA in the $5.50 range. I normally always look at the insider ownership before I start a position. I failed to do this, and I paid the Ultimate investors choice. Insider ownership is pathetic. Most insiders own 30,000 shares or less. The CEO holds a total of 800,000 that's it. This is the latest information I have.

Whether RFK is confirmed or not (I believe he and most of the nominees will be),

Given the lack of qualifications and low character, I sure hope most of the nominees are rejected.

I think it might be wise to anticipate a high degree of chaos from the incoming administration, which translates as volatility in the stock market.

Fully agree. I sold off half of my remaining RVNC and half of CDMO to generate a bigger cash cushion.

Whether RFK is confirmed or not (I believe he and most of the nominees will be), I think it might be wise to anticipate a high degree of chaos from the incoming administration, which translates as volatility in the stock market.

I hope that Kennedy is blocked from confirmation and I concur that it would be bullish for the biotech sector; however, I reject the notion that this is hugely consequential matter for ENTA one way or the other.

If Kennedy is block, this will surge. We should know relatively soon..

I added a little more today to push over 20k (excluding children) which is small potatoes compared rest of the Board. Anyone else notice that nearly every day for last two weeks the AH trades are higher than the Close. For example, i am seeing last trade at $5.23 with roughly 24,000 shares so far. Perhaps these trades are inaccurate because they are not actually AH -otherwise why would someone wait for extended trading/not use limit orders?

Yes, some across the board short activities for sure. But from the few bio names I follow, none of them have 5x-6x average volumes last few weeks. That kind of volume spike is unique to ENTA.

It almost felt like they deliberately wanted to ensure we closed in the red. Every time ENTA had a run-up to breakeven during the day, a surge in volume would come in and push it down by a couple of percent.

who the heck knows but my impression is because most bios fail and shorting across the board on average is a winning strategy some funds may do just that. In the meantime another down day (I can't remember the last time it was green) on 8x typical volume so same old same old
Maybe some folks who sold for tax reasons will buy later in the month since you have to wait a month for wash sale rules

It actually requires a lot more conviction to hold a short position on a name that is trading less than cash value than to go long. Was thinking maybe some funds blow up, but even that won’t take this long to clear the inventory.

it sure seems someone still wants out of a position or shorts are on the move, but it also must be the case that ENTA has become a trading name and you see the same shares changing hands multiple times a day, because otherwise it's hard to see the volume going from 100K a day to 500k+ day in day out

GSK has a large respiratory and asthma business so this should be in their wheelhouse should they wish to pursue the immunology side of KIT
incidentally THRD is down 38% the last 2 trading days. I know bios have been pressured but this seems extreme. They are due to present phase 1 healthy volunteer data (along w biomarker data) this quarter. I see no news

Thanks. I may have stretched by pigeonholing the GSK deal as immunology, but it does bring the potential for GSK to expand into KIT immunology, as you noted.

GSK is in oncology but it is targeted to KIT and like BPMC they could segue to cKIT immunology down the road
GSK oncology after a terrible start has been a bit of a bright spot for the company. I sold most of my shares but still have a small position

Recent Immunology Deals Pertinent to ENTA (for_yellow_sticky)

GSK-IDRx
$1.15B cash buyout (incl $150M regulatory milestone)
MoA: KIT
Stage: phase-1b
Reference: #msg-175655362

GILD-Leo
Global collaboration: $250M up-front; $1.7B biobucks
MoA: STAT6
Stage: preclinical
Reference: #msg-175651641

Yes, disappointing, although I can see ENTA is trying to go UP today but the selling pressure persists. It is weird. I don’t even know which entities have so many shares readily available to sell after so much selling already

I miss the days when deals like this, JNJ etc would be good for a nice upward push in biotechs
The GILD deal on top of these right in ENTA's space would have been good for 10% plus - shows you how bad sentiment is right now

GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

• IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability…

Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. IDRX-42 is in phase-1/1b clinical development.

Total is now 1.198 million shares. Pretty significant.

Top Institutional Holders
Farallon Capital Management LLC 2.11M Sep 30, 2024 9.95% 10,731,053
Vanguard Group Inc 1.98M Sep 30, 2024 9.35% 10,087,698
Blackrock Inc. 1.9M Sep 30, 2024 8.97% 9,672,644
Krensavage Asset Management, LLC 1.5M Sep 30, 2024 7.07% 7,625,196
This board
Morgan Stanley 1.1M Sep 30, 2024 5.20% 5,613,516

108k shares here

Wow, I assume Leo’s stat6 program is much further along compared to ENTAs’? But it can’t be that far as they are still pre-clinical?

Why would Gilead pay so much upfront for it? I think dewophile quoted another similar deal, $150mm iirc, and also preclinical.

Maybe the next partnership news would be ENTA but on immunology instead of RSV. ;)

Total is now 1.09mm shares - slightly over 7 percent of the public float.

If we were a fund, we would be the 5th largest holder, on par with MS. We should have a say on ENTA future direction ;)

Between family accounts and the portfolio I manage for a private foundation, there are 360K shares.

Wow, with the numbers Alertmeipp has now gathered that means ~1 million shares from this people who use this board. I am just an Academic scientist who is relatively poor so my shares would be a rounding error so are not worth mentioning. You money bags guys can buy me a drink if ENTA does come back and hits big! 😁 🥂

After the long ENTA decline it represents ~10% or

GILD, Leo Pharma ink STAT6 collaboration:

https://www.businesswire.com/news/home/20250111983856/en Gilead Sciences…and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.

…Targeting STAT6 has shown potential preclinically to treat a broad population of patients and provide an oral alternative to those currently treated with injectable biologics.

Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead development for potential topical formulations of STAT6 inhibitors.

…Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 program. LEO Pharma will have the option to potentially co-commercialize oral programs for dermatology outside the United States. LEO Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology.

LEO Pharma is eligible to receive up to $1.7 billion in total payments, including an upfront payment of $250 million. In addition, LEO Pharma may also receive tiered royalties ranging from high single-digit to mid-teens on sales of oral STAT6 products. Gilead may receive tiered royalties ranging from high single-digit to mid-teens on sales of topical STAT6 products.

Between family accounts and the portfolio I manage for a private foundation, there are 360K shares.

10K here

Total now 720k - 4.67% of the public float (15.44mm) just from a few of us.
Interesting
(720370 shares).

considering more at this level.

The risk reward has been great since it traded below net cash value.. just couldn't imagine it can go this low.

>> down over $200k

Nice job actually, I would love to trade your cost basis with you any time. ;)

I own 24,000.

33,200 shares and considering more at this level.

129,770 and down over $200k

Enta is ripe for an activist investor

Won't be surprised at all if it happens. Could be easy money as long as they can ensure the company be rational on its RSV program.

Thanks, we have 555k total now.

120k

FWIW - Another 250k plus traded after hours

I'm over 100k, so that's 2% of the float already.
Total is over 435k already.

FLO = 100K

BABY FLO = .01

I'm over 35k

I own 200k eom

I wonder how many shares this board own in total. Is there a way to do a tally in this board?

Some insider buys would be appreciated

Liquidation phase..

Enta is ripe for an activist investor

This is officially the ENTA theme song. "How low can you go"!

Why would you want bad news?

The JPM conference can't come soon enough for ENTA..

Same. I guess that's the fun of small biotech investing. Out sized moves are the norm on both sides. Just hope we have some real news that would justify the 70% down move from $13 few short months ago.

No doubt, got lucky there. Hopefully here as well.

You lucked out on RVNC most lost money there - that is an example of a distressed buyout for sure. I have one example where I lost money despite a buyout and that was ZGEN. Sure I made back some paper losses, but net net was a loss. Can't win them all

There is no better feeling

Agree, hope we get to enjoy the feeling with ENTA soon. I made ok money with RVNC buyout offer and another one in energy sector recently. Both companies were undervalued with good quality assets and the assets would worth more under larger companies.

Not happen often but the feeling was awesome when it did indeed,

I probably have too much ENTA now, largest position by far. Started averaging down way too early unfortunately. Feel it is pretty safe to own as well, and with enough upside to compensate the wait time. But didn’t expect this to drop to this low. I thought net cash value would provide a solid good floor. But now we need to double just to get back to that. Live and learn I guess.